Downloading...
Download

REGN

Regeneron Pharmaceuticals Q2-Q3 Confirmed "Troughing in ProgressIF we do not crash like many Elliottsions are suggesting implying of Grand 5th wave since 1929... iF we do not start WW3... IF everything utterly absolute out there in the pharmaceutical industries locally and globally... IF our studies of the relation between XLV and Regeneron Pharmaceuticals is remotely correct... Then we should have struck a trough or we shall see one in the next few months Q2-Q4 = We will see a big bullish move next ! *** Risk down is (-35%) ...
NASDAQ:REGN
by samitrading
Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-to-equity is 0.09x (extremely healthy) and earnings are forecast to grow 7.5% per year. While 2025 is anticipated to be its "worst" earnings year, the outlook through 2028 looks like steady growth in revenue and cash flow. From a technical analysis view, the stocks entered my "crash" simple moving average zone today (currently between $466 and $502). More often than not, this area signals a bottom in the near-term, but it's not guaranteed. I wouldn't be surprised if the $450s-$460s get hit before a reversal if the market shifts negatively - which will be another entry for me. If it moves into my "major" crash zone in the $300s to close more gaps on the daily chart, I will be piling into this stock heavily (like I did with NYSE:UNH ) for a longer-term hold - of course, unless fundamentals change. I'm going to keep my target small unless there is a "major crash" and eye the closing of the nearest price gap on the daily. There is another between $883-$914... Targets: $590 (+17.5%)
NASDAQ:REGNLong
by WorthlessViews
1
REGN Technical Analysis: Potential Bullish SetupREGN is currently at a strong weekly support level, having formed a double bottom with a clear bullish divergence on the daily chart. The price has also closed above a downward trendline, signaling a potential shift in momentum. While the price might be slightly resistant in the 668 - 686 zone, a strong close above this area could lead to further upside. Trading Recommendations: Entry Point (CMP): 594 Stop-Loss: Closing below 520 Take Profit 1: 686 Take Profit 2: Open Beyond the initial target, other potential targets include 740. After that, the price could look to fill a gap at 914, and potentially even hit 1200 as there appears to be no major resistance before that level. Happy trading!
NASDAQ:REGNLong
by TradeWithParas
NASDAQ-REGN at a Crossroads: Breakdown or Breakout?The Market’s Dilemma: Is REGN Ready for a Reversal? The biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) is hovering at a critical juncture. Trading at $672.98, the stock has plummeted 44.4% from its all-time high of $1211.19 just five months ago. With the RSI at 38.8, the market is edging toward oversold conditions—but does that mean a bounce is imminent, or is further downside in store? Recent sell volume spikes and bearish VSA patterns suggest institutional distribution, while key support at $669.24 is under pressure. If buyers fail to hold this level, the next move could be decisive. Meanwhile, resistance looms at $693.67, creating a tight battlefield between bulls and bears. With momentum indicators flashing caution and a looming test of critical levels, traders must ask: Is REGN poised for a short-term rally, or are we witnessing the start of an extended breakdown? Stay sharp—this might be the last chance to act before the next major move. NASDAQ-REGN Roadmap: A Pattern-Driven Journey The price action on Regeneron Pharmaceuticals (NASDAQ: REGN) has been painting a vivid picture of institutional maneuvering. By analyzing the sequential Volume Spread Analysis (VSA) and buy/sell volume patterns, we can uncover the footprints of smart money and determine where the next big move might emerge. Let’s break it down step by step. January 22: The Battle Between Bulls and Bears A VSA Buy Pattern Extra 1st appeared, signaling a potential reversal after prolonged selling. The open was at $682.89, but the close dipped to $679.24, showing hesitation. However, a competing Sell Volumes Max pattern on the same day added to the confusion. The key takeaway? The market was indecisive, but the tug-of-war suggested a major breakout was brewing. January 23: Buyers Step Up A surge in buy volumes confirmed the bullish bias. With an open at $692.165 and a close at $694.36, bulls showed their dominance. This validated the previous buy setup and confirmed that institutions were stepping in. January 24: A Bullish Fake-Out? The VSA Manipulation Buy Pattern 3rd hinted at continued strength. The market opened at $680.78 and closed higher at $683.75, pushing past short-term resistance. However, the presence of a Buy Volumes Takeover pattern earlier in the day, which was immediately sold off, hinted at hidden distribution. The market was climbing, but the undercurrent wasn’t as strong as it seemed. January 27-31: Sellers Take Control A clear shift in sentiment emerged as Sell Volumes Max patterns took over. On January 27, the market opened at $685.17 but barely moved, closing at $684.67—a sign of exhaustion. Then, on January 30-31, massive sell volumes hit, confirming distribution. The price tumbled from $684.17 to $676.50, sealing the bearish outlook. Key Takeaway: Where Do We Go From Here? The January 23-24 bullish patterns initially suggested an upside continuation, but the surge in selling pressure from January 27 onward negated that move. The market failed to hold its ground, confirming the strength of the selling signals. With support at $669.24 under fire, the next key zone to watch is $652-655. If bulls don’t reclaim momentum soon, REGN could be setting up for a deeper correction. Stay sharp—the next move is brewing. Technical & Price Action Analysis: Key Levels in Play The market structure on NASDAQ-REGN is shifting, and traders need to keep an eye on these critical levels. If support zones fail to hold, they flip into resistance—trapping late buyers and fueling further downside moves. Likewise, if resistance levels break, they become new bases for continuation plays. Support Levels: 669.24 – The immediate support zone; losing this level could open the floodgates for deeper selling. 592.7 – A major downside target if sellers gain full control. This level previously acted as a demand zone. 547.57 – The last stand for bulls before things get ugly. Below here, expect a momentum flush. Resistance Levels: 693.67 – The first wall bulls need to break for any short-term recovery. A failure here keeps the bears in charge. 707.835 – A psychological pivot; clearing this would suggest a trend shift. 752.54 – Major battle zone. If reached, expect serious profit-taking. 784.1 – Key breakout threshold; breaking and holding above opens the door for a bigger upside run. 810.53 – The big league level. Any rally stalling here signals trend exhaustion. Powerful Support Levels: 945.71 – Long-term structure zone. If the price ever reclaims this level, bulls are fully back in control. 985.9 – The pivot point for a full-blown trend reversal. 1175.16 – The holy grail for long-term investors; reclaiming this would signal a multi-month rally. Powerful Resistance Levels: 575.46 – A historical battleground; failure to hold here sends a strong bearish signal. 549.69 – A make-or-break level for dip buyers. If sellers push below, expect panic exits. The playbook is simple: react, don’t predict. Watch for confirmations, volume shifts, and price reactions at these levels. No clean break? No trade. The market always shows its hand—just follow the footprint. Trading Strategies Using Rays: Precision in Action The "Rays from the Beginning of Movement" concept is built on dynamic Fibonacci-based levels that adapt to market conditions. Unlike traditional support and resistance levels, these rays adjust automatically as price action evolves, providing a leading rather than lagging perspective. The goal is not to predict exact levels but to identify high-probability zones where price interactions signal trend continuation or reversal. These rays interact with VSA dynamics and moving averages, making them powerful confirmation tools. The price will move from ray to ray, establishing first, second, and third trade targets accordingly. Entries should be made only after interaction with the ray and confirmation of direction. Optimistic Scenario: Bullish Ray Interaction Entry near 669.24 (support level + interaction with a rising ray) First target: 693.67 (resistance level aligned with MA50) Second target: 707.83 (breakout level with confirmation from VSA) Third target: 752.54 (major resistance, completion of the wave) 💡 If momentum is strong, price could extend toward 784.1, aligning with long-term trend acceleration. Pessimistic Scenario: Bearish Ray Interaction Entry after breakdown of 669.24 (failure to hold as support flips to resistance) First target: 592.7 (next structural level, confirming bearish intent) Second target: 547.57 (full breakdown level, aligning with MA200 interaction) Third target: 575.46 (major psychological barrier—either reversal or trend continuation) 💡 If the bearish wave extends, price may push toward 549.69, signaling further downside. Potential Trades Based on Ray Interaction Buy from 669.24 → Target 693.67 – Confirmation required via VSA buy volumes. Breakout above 693.67 → Target 707.83 – Only valid if price holds above MA50. Sell below 669.24 → Target 592.7 – Valid only after a strong bearish volume surge. Rejection at 707.83 → Short to 669.24 – Reversal signal from VSA sell zones. Your Turn: Let’s Trade Smart Together! 🚀 If this analysis makes sense to you, hit that Boost and save this idea—because the key to trading is understanding the levels where trades can be executed. Follow how the price moves and compare it to my setup. The market always speaks to those who listen. Got questions? Drop them in the comments! Let’s break things down together. If you need an analysis of another asset, let me know—we can figure out the best way to do it. Some I can share for free, while for private setups, we can discuss the details. My strategy automatically plots all rays and levels, but the indicator is available only in Private. If you want to trade using this system, send me a direct message. These rays work on all assets, and price moves like clockwork along them. If you want me to chart your asset, hit Boost and comment below. The more interest, the higher the chance I’ll cover your instrument next! Follow me here on TradingView—no fluff, no hype, just **clear levels and market logic.**🔥
NASDAQ:REGNShort
by brandlabelden
1
$REGN LongThis is just my observation, but not an advice. Technical: REGN touched its two strong trendline since 2020 and 2021. REGN reached the 50% correction since 2020. REGN is oversold daily and weekly. A significant divergence is observable on daily chart. Price touched SMA 200. Fundamental: P/E: 16.9x (moderate undervalue) Since last ATH NASDAQ:REGN has come up with wide ranges of successful clinical trial outcomes. Nonetheless, prices dropped due to competitive pressures on Eylea. Last week, after significant clinical trial results of Odronextamab and Poze-Cemdi, the market moved up. However, the price slid after the BoA's PT revision. Analyst sentiments: 17 buy, 7 buy, 1 sell (BoA) The long possibility is high from now on.
NASDAQ:REGNLong
by jack_the_real_trader
EXCLUSIVE EWTX 350% BUY/HOLD techs/fundies with catalyst🔸Let's review EWTX daily price chart. Strong V-shape recovery in progress. YTD gains at 218% off the lows, which is an EXCELLENT indicator of the overall health of the stock. Trading 5% below 52 week high. 🔸Based on technicals, I envision a C*H breakout in 2025 after we hit overhead resistance we can expect a pullback in order to fill the massive liquidity gap left behind near 22 USD. currently stock is trading near 35 handle and expecting limited upside going forward into Q4 2024. Market cap is hovering near 3 Bln USD so it's not a penny stock and also market cap is not inflated. 🔸CYTK competitor stock chart on the right, similarly priced and also same line of business as EWTX. Trading at 53 USD now previously maxed out at 100 USD, current CYTK market cap is 6 Bln USD, at the peak market cap was 12 Bln USD. So potentially EWTX can do x4 from current levels in order to hit CYTK max market cap. this means x4 stock prices for EWTX from current levels, so it's 34 x 4 = 136 USD max projected stock price. 🔸My PT for EWTX in 2025 is 100 USD, based on the technicals and fundamentals. Recommended strategy bulls: wait for pullback/rejection from overhead resistance and be ready to BUY/HOLD once we do a COMPLETE gap fill of the liquidity gap near 22 USD. Target is 100 USD, 350%+ upside from entry price. Good luck traders! 🔸Below supplementary fundies info on EWTX / some info on the positive catalysts, you can dig deeper if required. 🔸Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious muscle diseases, particularly rare neuromuscular and cardiac disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company leverages its deep expertise in muscle biology to create innovative therapies aimed at unmet medical needs. 🔸Their lead product candidate, EDG-5506, is being developed to treat Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). This small molecule is designed to prevent contraction-induced muscle damage, offering potential benefits in improving muscle function for patients with ystrophinopathies. The drug is currently in Phase 2 trials, and has shown promising results in reducing muscle damage biomarkers​ ​ 🔸Another key program focuses on EDG-7500, an experimental therapy for hypertrophic cardiomyopathy (HCM). This drug is a selective sarcomere modulator designed to improve cardiac relaxation and contraction. The company initiated Phase 1 trials for EDG-7500 in 2023​. ​ 🔸Edgewise is dedicated to both advancing scientific research and engaging with patient communities, frequently collaborating with organizations such as the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy 🔸The biotech company tested its drug, EDG-7500, in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy. In this disease, a genetic mutation causes the heart ventricles to thicken. This limits cardiac function and exercise capacity. 🔸After a single dose, patients showed improved blood flow from the left ventricle. But sometimes drugs can do their job too well, suppressing cardiac function — a measure known as reduced left ventricular ejection fraction, or LVEF. But patients didn't show meaningful reductions in LVEF. 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:EWTXLong
by ProjectSyndicate
13
IS THE REGENERON PHARMACEUTICALS INC IS READY FOR A NEW ALL-TIMEIs Regeneron Pharmaceuticals ready for a new all-time high, or will it test again the previous one at $620 from October 2020 and confirm it as a strong resistance? Regeneron Pharmaceuticals is a leading-edge biotech and pharmaceutical company that focuses on cytokines and tyrosine kinase receptors at the cellular level. First, Regeneron developed an experimental antibody cocktail to treat COVID-19 called REGN-COV2. This treatment was granted emergency use authorization by the FDA and was even provided to former President Trump when he contracted the virus. They have a diverse product offering outside of COVID-19 offerings and some exciting possibilities in their pipeline. Also, they recently announced a new partnership with the British pharmaceutical company AstraZeneca to research and developed small molecule compounds targeting the GPR75 gene. This is also promising because the Regeneron Genetics Center discovered the GPR75 gene to be a key factor in developing obesity, a disease that over 650 million people suffer from around the world. It is inspiring when you consider that the comorbidities associated with obesity can manifest as a significant cost to insurance companies, making the drug more marketable. Over the past couple of years, the growth of the generics industry has been staggering, and Regeneron is fast becoming a major player. On August 5, the company announced its results for the second quarter of the year by beating the forecast results and publishing a better revenue and EPS. Fundamentally the company looks ready for a new all-time high, but dividends and share purchases are the areas where the company becomes a bit complicated. It is focused on its funds on R&D and has done exceptionally well, but it does not currently pay a dividend, and the net buyback rate is low. It is interesting how the investors will react at these price levels because it looks like that the price revert and confirm the $620 price level as a strong resistance. But if this correction in the long uptrend is temporary, the price easily reaches the previous all-time high at $666 and try to break through it. But it is also possible to picture the graph we saw between October and December last year in a downward direction to the price levels of $540 or far on South to $467. Looking at oscillator indicators, we can see that the correction starts from the RSI overbought zone. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carry a high-risk level. By registering and signing up, any client affirms their understanding of their accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals; therefore, it cannot be held liable nor guarantee any profits or losses.
NASDAQ:REGN
by legacyFXofficial
BioNTech $BNTX making a breakout from flag patternNASDAQ:BNTX is in a strong uptrend, and last week tested its 50 day MA and its bouncing really good. Today is in focus as the price broke out a continuation pattern with good volume. Also, the MACD is close to make a buy signal with a bullish crossover. BioNTech has a IBD relative strength rating of 97 and is Rank #2 in its industry, just behind NASDAQ:REGN which doesn't have good technicals. With this buy signal I have a target sell on $266.50 with a 2:1 risk/reward ratio.
NASDAQ:BNTXLong
by dpuleo19
ridethepig | Regeneron Pharmaceuticals📌 REGN pipeline (with particular focus on the early stages) CEMIPLIMAB, REGN3767, REGN1979, REGN4018, REGN5458, REGN5459, REGN5678, REGN5093, REGN5713-5714-5715 and REGN-COV2 all have a lot of potential with particular focus around oncology. As can be see with GILD, the covid positioning has already moved on a lot: we are ready to play chapter II and REGN is a name worth considering for those looking to add single stock opps to their portfolio. Buyers are clearly exercising control here on the Monthly chart at $600. To the topside there is very little in-between here and $1,000 as the next big level. Thanks as usual for keeping the feedback coming 👍 or 👎
NASDAQ:REGNLong
by ridethepig